Mobile health applications for supporting self-management of oral systemic anticancer therapy in haematological malignancies: A systematic review of acceptability and efficacy

移动健康应用程序在支持血液系统恶性肿瘤患者自我管理口服全身抗癌治疗中的应用:可接受性和有效性的系统评价

阅读:1

Abstract

BACKGROUND: The acceptability and impact of mobile health (mHealth) applications on health outcomes in haemato-oncology remain unclear, particularly for patients undergoing long-term oral systematic anticancer therapy (SACT). PURPOSE: This systematic review investigated the acceptability and efficacy of mHealth applications in facilitating self-management of oral SACT in patients with haematological malignancies. METHODS: We conducted a comprehensive search of five electronic databases, PubMed, PsycINFO, CINAHL, Cochrane Library, and Web of Science, until October 2024, and extracted data, including methodologies, application names, functionalities, and key results. This was followed by a narrative synthesis of quantitative outcomes, and a thematic analysis of qualitative data. RESULTS: Eight studies were included, comprising three qualitative studies, one randomised controlled trial, one non-randomised trial, and three mixed-method studies. mHealth applications for self-managing oral SACT exhibited acceptability, with usability and satisfaction ratings between 60% and 78%. Using the Normalisation Process Theory, four themes influencing acceptability were: (1) coherence - perceived benefits, (2) cognitive participation - barriers from technical issues, (3) collective action - burden from excessive notifications and inadequate support, and (4) reflexive monitoring - integration challenges in daily routine. Despite no major clinical or behavioural improvements, mHealth applications enhanced patient awareness of support, online health knowledge, and reduced daily life impact. CONCLUSION: Fostering effective self-management of oral SACT in patients with haematological malignancies requires addressing issues such as application glitches, notification fatigue, and integration barriers to optimise these interventions. Future well-designed clinical trials are warranted to validate the impact of these applications on patient outcomes in cancer care.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。